Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies

Clinical Immunology

Volumn 139, Issue 2, 2011, Pages 133-141

  Berger, Melvin ^a   Rojavin, Mikhail ^a   Kiessling, Peter ^b   Zenker, Othmar ^b  

^a CSL Behring LLC   (United States)

^b CSL BEHRING GMBH   (Germany)

Author keywords

Intravenous igG; Pharmacokinetics; Primary immune deficiency diseases; Replacement therapy; Serum igG level; Subcutaneous igG; Trough igG level

Indexed keywords

HIZENTRA; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGAMMAGLOBULINEMIA; AGED; AREA UNDER THE CURVE; ARTICLE; CHILD; COMMON VARIABLE IMMUNODEFICIENCY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; STEADY STATE;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BODY MASS INDEX; BRAZIL; CHILD; EUROPE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 79954600098     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.01.006     Document Type: Article

References (32)

1. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol. Allergy Clin. N. Am. 2008, 28:413-437.
2. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., Buckley R., Chinen J., El-Gamal Y., Mazer B.D., Nelson R.P., Patel D.D., Secord E., Sorensen R.U., Wasserman R.L., Cunningham-Rundles C. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 2006, 117:S525-S553.
3. Berger M. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J. Clin. Immunol. 2007, 27:628-633.
4. Bjorkander J., Nikoskelainen J., Leibl H., Lanbeck P., Wallvik J., Lumio J.T. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang. 2006, 90:286-293.
5. Ballow M. Immunoglobulin therapy: methods of delivery. J. Allergy Clin. Immunol. 2008, 122:1038-1039.
6. Stiehm E.R., Casillas A.M., Finkelstein J.Z., Gallagher K.T., Groncy P.M., Kobayashi R.H., Oleske J.M., Roberts R.L., Sandberg E.T., Wakim M.E. Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product. J. Allergy Clin. Immunol. 1998, 101:848-849.
7. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin. Immunol. 2004, 112:1-7.
8. Berger M., Cupps T.R., Fauci A.S. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann. Intern. Med. 1980, 93:55-56.
9. Chouksey A., Duff K., Wasserbauer N., Berger M. Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin. Immunol. 2005, 1:120-130.
10. Gardulf A., Bjorvell H., Gustafson R., Hammarstrom L., Smith C.I. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin. Exp. Immunol. 1993, 92:200-204.
11. Gardulf A., Nicolay U., Math D., Asensio O., Bernatowska E., Bock A., Costa-Carvalho B.T., Granert C., Haag S., Hernandez D., Kiessling P., Kus J., Matamoros N., Niehues T., Schmidt S., Schulze I., Borte M. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J. Allergy Clin. Immunol. 2004, 114:936-942.
12. Ochs H.D., Gupta S., Kiessling P., Nicolay U., Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J. Clin. Immunol. 2006, 26:265-273.
13. Radinsky S., Bonagura V.R. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J. Allergy Clin. Immunol. 2003, 112:630-633.
14. Hizentra immune globulin subcutaneous (human) [package insert] 2010, CSL Behring LLC, Bern, Switzerland.
15. European Agency for the Evaluation of Medical Products Human Medicines Evaluation Unit. Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use (CPMP/BPWG/283/00), (2002).
16. Gardulf A., Nicolay U., Asensio O., Bernatowska E., Bock A., Carvalho B.C., Granert C., Haag S., Hernandez D., Kiessling P., Kus J., Pons J., Niehues T., Schmidt S., Schulze I., Borte M. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J. Clin. Immunol. 2006, 26:177-185.
17. Vivaglobin immune globulin subcutaneous (human) [product information] 2006, ZLB Behring GmbH, Marburg, Germany.
18. Orange J.S., Grossman W.J., Navickis R.J., Wilkes M.M. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin. Immunol. 2010, 137:21-30.
19. Chapel H.M., Spickett G.P., Ericson D., Engl W., Eibl M.M., Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J. Clin. Immunol. 2000, 20:94-100.
20. Desai S.H., Chouksey A., Poll J., Berger M. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J. Allergy Clin. Immunol. 2009, 124:854-856.
21. Gustafson R., Hammarstrom L. Subcutaneous immunoglobulin replacement therapy. Ellipse 2002, 18:45-48.
22. Waniewski J., Gardulf A., Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J. Clin. Immunol. 1994, 14:90-97.
23. Berger M., Murphy E., Riley P., Bergman G.E. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med. J. 2010, 103:856-863.
24. J.B. Hagan, M.B. Fasano, S. Spector, R. Wasserman, I. Melamed, M.A. Rojavin, O. Zenker, J. Orange, Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency, Blood, Manuscript in development.
25. S. Jolles, E. Bernatowska, J. De Gracia, M. Borte, V. Cristea, H.H. Peter, B.H. Belohradsky, V. Wahn, J. Neufang-Huber, O. Zenker, B. Grimbacher, Efficacy and safety of IgPro20 in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy, Clin Immunol, Manuscript in development.
26. Thepot S., Malphettes M., Gardeur A., Galicier L., Asli B., Karlin L., Gerard L., Laumont R., Doize M.L., Arnulf B., Fieschi C., Bengoufa D., Oksenhendler E. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J. Clin. Immunol. 2010, 30:602-606.
27. Wasserman R.L., Irani A.M., Tracy J., Tsoukas C., Stark D., Levy R., Chen J., Sorrells S., Roberts R., Gupta S. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin. Exp. Immunol. 2010, 161:518-526.
28. Immune Deficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey, (2003) Available at: Accessed January 2007, 2011. http://www.primaryimmune.org/publications/surveys/Treatment_Experiences_and_Preferences_(2003).pdf.
29. Bonagura V.R., Marchlewski R., Cox A., Rosenthal D.W. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J. Allergy Clin. Immunol. 2008, 122:210-212.
30. M. Lucas, M. Lee, J. Lortan, E. Lopez-Granados, S. Misbah, H. Chapel, Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22years, J Allergy Clin Immunol, 125 (2010) 1354-1360, e1354.
31. Bonilla F.A. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol. Allergy Clin. N. Am. 2008, 28:803-819.
32. Wang W., Wang E.Q., Balthasar J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 2008, 84:548-558.